EVALUATION OF THE PROFILE OF ADVERSE EVENT NOTIFICATIONS FOR IVERMECTIN AND NITAZOXANIDE BEFORE AND DURING THE COVID-19 PANDEMIC
Palavras-chave:
COVID-19, Ivermectin, Nitazoxanide, adverse eventsResumo
COVID-19, caused by the SARS-CoV-2 virus, was discovered in 2020, with the pandemic originating in Hubei, China, in December 2019, and spreading rapidly worldwide. Patients presented symptoms of acute respiratory infection, with some progressing to severe complications such as acute respiratory distress syndrome (ARDS) and respiratory failure. Fear and the rapid spread of the disease led to an increase in self-medication with drugs such as ivermectin, azithromycin, chloroquine, and nitazoxanide, whose efficacy against COVID-19 was unproven. This study aimed to analyze the profile of adverse event notifications associated with nitazoxanide and ivermectin before and during the pandemic, using data from the VigiMed platform. The comparative analysis of the periods revealed a significant increase in adverse event notifications during the pandemic, highlighting the expanded and unfounded use of these medications. Furthermore, notifications increased in number and severity, with an emphasis on self-medication and changes in the profile of notifiers. In conclusion, the findings underscore the need for clear, evidence-based communication by health authorities and continuous surveillance of the off-label use of medications, especially during public health crises, to prevent an increase in adverse events and the overload of health systems.
Referências
Al-KURAISHY, H.M., et al. Nitazoxanide and COVID-19: A review. Mol Biol Rep, v. 49, p. 11169–11176, 2022.
BACARALDO-SANTAMARÍA, D. et al, Segurança medicamentosa de medicamentos e substâncias de uso frequente para automedicação na COVID-19. Avanços Terapêuticos na Segurança de Medicamentos, v. 13, p. -14, 2022.
BEZERRA, M.M.A. et al. Medicamentos na pandemia da COVID-19: Análise da comercialização de azitromicina, hidroxicloroquina, ivermectina e nitazoxanida no Brasil. Research, Society and Development, v. 11, n. 6, 2022.
CALY, L. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, v.178, 2020.
CHEN, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, v. 395, n. 10223, p. 507-513, 2020.
HEIDARY, F.; GHAREBAGHI, R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics, v.73, p.593-602, 2020.
HENTSCHKE-LOPES, M. et al. Sales of “COVID kit” drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency. Cad. Saúde Pública, 2022, v. 38, n. 7.
LOPES, M.H. et al. Sales of “COVID kit” drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency. Cad. Saúde Pública, v. 38, n. 7, p. 1-10, 2022.
MATUOKA et al. Nitazoxanida no tratamento de COVID-19 revisão sistemática rápida. Oxford Brazil EBM Alliance, p.1-24, 2020.
MELO, J.R.R., et al. Automedicação e uso indiscriminado de medicamentos durante a pandemia da COVID-19. Cad. Saúde Pública, 2021; v. 37, n. 4.
OLIVEIRA, F.B.M. et al. Uso de ivermectina e atazanavir no tratamento da covid-19: uma revisão de escopo. Arquivos de Ciências da Saúde da UNIPAR, Umuarama, v.27, n.3, p. 1047-1128, 2023.
Orjuela-Rodríguez, T. et al. Reacciones adversas a medicamentos utilizados para la COVID-19 en cinco países de América Latina. Rev Panam Salud Publica, v. 46, 2022.
PAUMGARTTEN, F.J.R.; XAVIER DE OLIVEIRA, A.C.A. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Ciência & Saúde Coletiva, v. 25, n. 9 p. 3413-3419, 2020.
SANTOS-PINTO, C.D.B.; MIRANDA, E.S.; e OSORIO-DE-CASTRO, C.G.S. O “kit-covid” e o Programa Farmácia Popular do Brasil. Cad. Saúde Pública, 2021; v. 37, n. 2.
